

Disclaimer :

The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudices the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.

M.11074 • L-GAM / EPIC BPIFRANCE / BIOSE

SECTION 1.2

Description of the concentration

On 30 March 2023, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004.

The concentration consists of the acquisition by L-GAM and EPIC Bpifrance of joint control, within the meaning of Article 3(1)(b) and Article 3(4) of Council Regulation (EC) No 139/2004, of Biose Industrie SAS, a biotechnology company specialized in the microbiome sector.

The Parties' activities are as follows:

- L-GAM is an investment company based in Luxembourg that makes long-term investments in small and medium-sized private companies in Europe,
- EPIC Bpifrance is a French State public industrial and commercial institution which promotes the development and financing of small and medium-sized companies, for the account of the French State,
- Biose Industrie is a contract development manufacturing organisation, dedicated to Live Biotherapeutic Products (LBP) process development and production.